| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is | Revenue for the current quarter has increased by 14.6% compared to the same quarter of the last year, driven by continued momentum across key therapeutic areas - notably Ophthalmology, Dermatology and General Medicine - and key geographies including KSA, Gulf and Iraq. In addition to institutional sales, ramp-up of recent new launches, and enhanced commercial execution. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | Net profit increased by 23.4% during the current quarter compared to the same quarter of the last year primarily driven by enhanced operational efficiencies, disciplined cost management, and improved margin leverage across the business. |
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is | Revenue for the current quarter has declined by 13.4% compared to 1Q 2025, in line with expectations, as 1Q sales are generally higher than the rest of the year due to strategic seasonality. |
| The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is | The Company’s net profit decreased by 15.9% during the current quarter compared to the 1Q 2025, due to the decrease in revenue as stated above, in addition to a slight increase in employee related costs stemming from the implementation of the revamped employee rewards program in 2Q 2025. |
| The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is | Revenue during the current period has increased by 16.8% compared to the same period of the last year, driven by consistent execution across commercial, operational, and strategic pillars. In addition to the performance across core therapeutic areas and key geographies. |
| The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is | Net profit during the current period has increased by 37.7% compared to the same period of the last year, driven by improved operating leverage, reduced finance costs, and share of profit from the Algerian joint venture. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | The Group’s consolidated financial statements for the year ended 31 December 2024 were audited by another auditor who expressed an unmodified opinion on those consolidated financial statements on 4 March 2025 (corresponding to 4 Ramadhan 1446H). Further, the interim condensed consolidated financial statements of the Group for the three-month and six-month periods ended 30 June 2024 were reviewed by another auditor who expressed an unmodified review conclusion on those financial statements on 7 August 2024 (corresponding to 3 Safar 1446H). |
| Reclassification of Comparison Items | None |
| Additional Information | Please refer to the attached Earnings Release for detailed information on the 1H 2025 results. |
| Attached Documents | Attached Documents |
